A new approach called reverse metabolomics has discovered molecules that may serve as a biomarker or a therapeutic target for IBD.
List view / Grid view
This episode defines allogeneic cell therapy as the administration of cells to a patient for therapeutic use, that were not initially taken from that patient.
New research from Cincinnati Children’s Hospital Medical Center suggests blocking IL-22 and IL-1R could offer a promising IBD treatment.
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
Researchers at Synlogic are clearing the path for a new class of medicine – biotherapeutics based on synthetic biology, called synthetic biotics, which are created by programming or engineering bacteria to metabolise or secrete well-validated targets of disease pathophysiology. In this article, Dr Caroline Kurtz, Chief Development Officer at Synlogic, discusses how synthetic…
New study has demonstrated that mice deficient in dendritic cell immunoreceptor are resilient against colitis and colonic tumour growth.
Removing stress hormones in mouse models restored proper function to immune cells and epithelial cells, pointing to new Crohn's treatments.
The Gut Cell Atlas comprises 428,000 cells in the gut and sheds light on the origin of Crohn’s disease and other intestinal diseases.
Dr James Woody discusses off-patent indications for anti-TNF to address unmet patient needs in pain, inflammation and beyond.
A novel nanotherapy can decrease intestinal inflammation and shrink lesions in rodent models of Crohn's disease, a study has shown.
Anti-inflammatory therapies for inflammatory bowel disease could aid recovery from COVID-19 as they target an enzyme involved in both diseases.
Regulatory T cells (Tregs) play a key role in regulating our immune system and inflammatory processes. Sangamo Therapeutics is evaluating the potential of CAR-Tregs (Tregs genetically modified with a chimeric antigen receptor, or CAR) for the development of therapies for immunological diseases, such as Crohn’s disease and multiple sclerosis, as…
A team has developed a predictive tool called TransComp-R which could be used to reveal whether new drugs that have been effective in animals will have positive outcomes in humans.
Recent research into why autoimmune disorders affect women four times more frequently than men has revealed several novel therapeutic targets that may lead to the development of future treatments.